explore -WSS

explore

author：comprehensive 2025-09-03 03:44:52 - browse：32638

Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to say someone overpaid?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how biotech’s downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.

For more on what we cover, here’s more on Gilead; here’s the news on Inhibrx; here’s the latest on biotech venture capital; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Food makers to regulators: Ultra

WSS

MassMutual is introducing free genetic testing for members

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Cancer researcher Catriona Jamieson is sending tumors into space

Dogs on Prozac: What pet anti

Food makers tried to stack nutrition panel with preferred experts

Bird flu in milk supply is likely coming from asymptomatic cows

leisure time

explore

hotspot

The high cost of giving birth even with insurance

Pig kidney works a record two months in donated body

Drug repurposing or repositioning? The language matters

UnitedHealth financials solid despite Change Healthcare cyberattack

Virginia high school admissions case could be legal follow

Q&A: Jennifer Adair on making gene therapy available globally

State Dept. review finds Biden bears some blame for Afghanistan failures

Close Medicare's dangerous gaps in addiction treatment coverage

Heart attack and stroke risk calculators need revising

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

hotspot

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Food makers to regulators: Ultra

Acelyrin, a rare IPO success, stumbles in its first big test

Generate Biomedicines machine learning biotech raises $273M

Food makers to regulators: Ultra

Generate Biomedicines machine learning biotech raises $273M

focus

knowledge

focus

Wikipedia